**A review on: Ophthalmic Drug Dosage Form**

**1.Introduction:**

 Ophthalmic formulation has been one of the most important and growing area of pharmaceutical expertise for decades. The main reason why scientist is still so interested in these form of drugs is the problem of low bioavailability of the drug after application to the eyeball. Caused, among others, by the complex anatomical structure of the eye, the small absorptive surface and low transparency of the cornea, lipophilicity of the corneal epithelium, metabolism, enzymatic decomposition, drug binding to proteins confined in tears. And defence mechanisms. that is, the formation of tears, blinking and flow of this substance into the nasolacrimal duct. (1) Ophthalmic drug delivery systems may be preferred over other delivery system despite their potential risk and complications. Additionally, compared with oral drug delivery systems, ocular drug delivery system may provide better equivalent bioavailability in the eye. Many method have been tested to recover the rate and/or extent of ophthalmic drug bioavailability, controlled dose release and, thus, improve therapeutic efficacy and reduce drug side effects. (2) Ophthalmic drug delivery system may be superior to another delivery system, regardless of its jeopardies and complications. (4,5) New drug formulation, researched in recent years, aim to achieve controlled release. From the drug to the tissues of the eyeball, including multicompartment delivery systems, inserts, collagen shields, contact lenses and so-called topical gels. (6,7,8) Low viscosity eye drops will drain quickly, especially if the drops are large, and absorption of active ingredients through the nasolacrimal duct may lead to systemic side effects. (15) The medication is applied to the surface of the eye for two purposes. For external treatment of the eye for infections such as conjunctivitis, blepharitis, keratoconjunctivitis sicca or for intraocular treatment through the cornea for diseases such as glaucoma or uveitis. Most eye diseases are treated with topical application of solutions used as eye drops. These common dosage forms account for nearly 90% of the dosage formulas currently on the market. Eye drops used as soluble drugs need to be instilled regularly with a concentrated solution. The practical reasons for choosing the solutions are the overall cost advantage, greater simplicity in formulation development and manufacturing, and good patient acceptance despite some ambiguity (Fitzgerald and Wilson, 1994). One of the major problems encountered with the use of topical ophthalmic medication is the rapid and extensive loss of the anterior corneal area due to drainage and excessive tear flow. After instillation of eye drops, less than 5% of the topical dose penetrates the cornea and reaches the intraocular tissues, whereas a large portion of the drop dose is usually absorbed systemically over the conjunctiva and nasolacrimal duct (lang, 1995) (16).

**2. Anatomy and physiology of the eye:**

The eye is the organ of vision. It is located in the orbital cavity and is innervated by the optic nerve (second cranial nerve). It has an almost round shape and is about 2.5 cm in diameter. The space among the eye and the orbit is occupied by fatty tissue. The bony wall of the eye socket and fat help protect the eye from injury. The first is the anterior part, which contains the cornea, conjunctiva, aqueous humour, iris, ciliary body, and lens. The second is the posterior part which include the retina, choroid, sclera and lens. The blood-eye barrier includes the blood/aqueous barrier and the blood-retinal barrier. They are noticeable barriers between the blood and the eye, playing a key role in penetration and destruction of ophthalmic drug and maintaining homeostatic control. The blood-retinal barrier is a posterior barrier consisting of an innermost barrier in the endothelial membrane of retinal vessel and an outer barrier in the retinal pigment epithelium. (3) The eyeball is made up of many layers with a specific structure and is divided into two segments. The first is the anterior part which include the cornea, conjunctiva, aqueous humour, iris, ciliary body and lens. The second is the posterior part that involves the retina, choroid, sclera, and lens. (37) The eye is spherical, located in the eye socket and protected by the eyelids. With a diameter of 24 mm and a volume of 6.5 cm3, it weighs about 7.5 g. Several layers with a specific structure make up the eyeball and divide it into two segments. (38) The eye is one of the most complex organs in the human body. In the human eye, three layers can be distinguished. The outer region is made up of the cornea and sclera. The iris controls the size of the pupil and therefore the amount of light reaching the retina; the ciliary body controls the strength and shape of the lens and is where fluid is produced; and the choroid is a vascular layer that provides oxygen and nutrients to the outer layers of the retina. The inner layer of the eye is the retina, a complex structure composed of many layers of nerve cells that sense and process light. The three transparent structure surrounded by layer of the eye are called the aqueous layer, lens, and lens. (39) (fig:1)



In fig.1 Eye anatomy

**1.Sclera (white part)**

 The sclera is hydrated and has huge, randomly arranged collagen fibbers; therefore, it is opaque and white rather than vibrant. The sclera has three layers: episcleral, the outer layer; sclera; and the melanocyte layer, the inner lamina fusc. (19) The sclera is a hard white layer of skin (made of tissue) that covers the entire eyeball except the cornea. The whites of the eyes help the eyeball connect with the muscles. (3)

 

**2.Cornea (clear lens in front of eye):**

The cornea is the most anterior part of the eye, in front of the iris and pupil. This is the tissue with the darkest nerve distribution in the body and most corneal nerves are sensory nerves, initiating from the ophthalmic branch of the trigeminal nerve. The cornea of ​​the adult eye has an average horizontal diameter of about 11.5 mm and a vertical diameter of 10.5 mm and a fairly constant curving throughout life. Five layers can be distinguished in the human cornea: epithelium, bowman's membrane, lamina propria, Descemet membrane and endothelium. (39)

**3.Retina:**

The sensory retina covers the inner part of the posterior 2/3 of the earth's wall. It is a gentle structure; in its living state it is transparent and has a purple-red colour due to the rod's purple colour when seen. The retina is a multilayered sheet of neural tissue tightly attached to a layer of pigment epithelial cells. (40) The retina is the tissue that lines the innermost surface of the eye, surrounding the vitreous cavity. During embryogenesis, the spinal retina develops from the optic cup. The latter is formed by the invagination of the optic vesicle, which is a natural development of the embryonic forebrain. The inner wall of the optic cup (surrounding the vitreous cavity) eventually become the neural retina; the outer wall (surrounded by the choroid and sclera) become the retinal pigment epithelium (rape). (fig:2) (39)



**In fig.2 Retina**

**3.Topical ophthalmic drug dosage forms:**

**3.1 Liquid ophthalmic drug forms:**

Liquid ophthalmic drug delivery system includes the following dosage forms:

**3.1.1. Eye drops:**

Eye drops are reachable in the forms of water and oil solutions, emulsions, or suspensions of one or more active ingredients, which may contain preservatives if stored in multiuse packaging. These forms are sterile and isotonic. The optimum ph. For eye drops equals that of tear fluid and is about 7.4. In deciding whether to buffer the drug in this form, one should consider the stability of active ingredient and the tissue tolerance to the preparation. (9) If the Ph value gets outside the range of 4–8 which is tolerated by eye, the patient may feel discomfort, there may be irritation, and the drug bioavailability can decrease because of increased tearing. (10) Eye drop is sterile and mainly isotonic solution containing drug or only lubricating or tears replacing solution. This conventional dosage form for ocular administration represents 90% of the marketed formulation due to its simplicity of development and production. Eye drops are cheaper than the other forms and have a good acceptance by patient. Unfortunately, 95% of the drugs are eliminated with the lachrymal apparatus and the different barriers in 15 to 30 s after the instillation. Moreover, a secondary eye infection may be caused by a microbiological contamination with multidose packaging (36).

**3.1.2. Ophthalmic solution:**

Ocular solution is a sterile aqueous solution used to clean and rinse the eyeball. They may encompass excipient that regulate, for example the osmotic pressure, Ph and viscosity of the composition. They may also encompass preservatives if stored in reusable packaging. (9)

**3.1.3 Microemulsion:**

Microemulsion is a promising drug formulation, inexpensive to produce, easy to sterilize and stable, capable of introducing larger amounts of active ingredient. In vivo studies and clinical tests on healthy volunteers have demonstrated a long effect and increased bioavailability of drugs applied in these form. The mechanism of action involves the adsorption of nanoparticles forming a drug reservoir and an internal microemulsion phase on the corneal surface, helping to limit discharge. Active ingredient that have been developed for microemulsions include cyclosporin a difluorinated, flurbiprofen acetyl, and flurbiprofen prodrug. (11)

**3.1.4. Prodrug:**

Changing the properties of a drug by developing a prodrug also increases the drug's permeability through the cornea. This method involves modifying the chemical structure, giving the active ingredient new properties, specifically selectivity and site specificity. Examples of drug substance that have been developed as prodrugs include epinephrine, phenylephrine, timolol, and pilocarpine. (12.13)

**3.1.5. Modification of liquid dosage forms for eye use:**

In the process of technological research on dosage forms, many methods have been proposed to prolong the contact time of liquid dosage form with tissues. Eyes, as well as increasing the absorption of active substances by these tissues. These modifications include the addition of viscosity increasing agents, introduction of drug penetration improvers into the formulation, use of prodrugs or cyclodextrin. (8,13)

**3.1.6. Cyclodextrin:**

Cyclodextrins are cyclic oligosaccharides capable of creating complexes including active ingredients, thereby increasing the water solubility of hydrophobic compounds without changing their molecular structure. (7,27) As transporters, they retain hydrophobic drugs in solution and transport them to the biofilm surface. In the case of eye drops, optimal bioavailability of the active ingredient is attained at an appropriate concentration of cyclodextrin (<15%) in the eye drop solution (8).

**3.2. Semi-solid ophthalmic drug formulations**:

Semi-solid ophthalmic drug delivery systems include the following dosage forms: **3.2.1. Topical gel (or sol-gel system):**

Topical gel is viscous liquid, demonstrating the ability to undergo a soul-gel transition when influenced by external factors, such as Ph, temperature, and the presence of suitable electrolyte. This property decelerates down the drainage of the drug from the ocular surface and increases the bioavailability of the active substance. Polymer used in the development of these formulations include gellant gum, poloxamer and cellulose acetate phthalate, while active ingredients used during topical gel research include ciprofloxacin. Hydrochloride, timolol maleate, fluconazole, ganciclovir and pilocarpine. (7,8)

**3.2.2. Eye ointments:**

Ointments are semisolid dosage forms for external use, usually consisting of solid or semisolid hydrocarbon base of melting or softening point close to human body temperature. After applying the ointment to the eye, it decays into small drops, which stay for a longer time period in conjunctival sac, thus increasing drug's bioavailability. Eye ointments have certain disadvantages although they are well tolerated and safe, they cause, among other things, blurring of vision and occasionally have irritating effects, because of which they are mainly applied night-time. (14) Eye ointments are prepared in a semisolid base- e.g. Simple eye ointment bp, which incorporates yellow soft paraffin (eight parts), liquid paraffin (1 part), and wool fat (1 part). The base is filtered while molten to get rid of particles and sterilized at 160°c for 2 hours. The drug is combined in advance than sterilization if heat-stable or added aseptically to the sterile base. Finally, the product is packaged aseptically in sterile aluminium or plastic tubes. Since the product contains nearly no water, the risk of microbial growth inside the ointment is negligible. (41)

**3.3. Solid eye drops:**

Solid ophthalmic drug delivery system include the next dosage forms:

**3.3.1. Coated contact lenses:**

This form of medication can absorb water-soluble substance on its surface, releasing after application to the eyeball for a longer period of time. The first and most broadly used polymer in lens manufacturing is poly (2-hydroxyethyl methacrylate) cross-linked with a small amount of ethylene glycol dimethyl acrylate (8,13).

**3.3.2. Eye drops:**

Eye drops are solid or semi-solid dosage forms that have no disadvantages compared to traditional ophthalmic formulations. They are fewer sensitive to protective mechanisms such as nasolacrimal duct flow, suggesting the ability to persist in the conjunctival sac for longer periods of time and additional stably. Then conventional dosage forms. Their undoubted advantages over conventional forms are also precise dosage, the ability to slowly release the substance at a continuous rate and limit its systemic absorption. In addition, their use allows you to reduce the frequency of taking the drug, as well as side effects and blurred vision. (17) The main factors limiting the use of supplements in therapy remain the reluctance of patients to abandon traditional dosage forms, the feeling of foreign bodies in the eye and sporadic failures to use and insert the insert, such as unnoticed secretion from the eye. (18)

**3.3.3. Soluble eye drops (soda):**

This form of ophthalmic drug delivery system was originally industrialised so that astronauts could apply it in microgravity. Sodi is a soluble ocular insert in the form of small oval platelet produced from acrylamide, 𝑁vinylpyrrolidone and ethyl acrylate. After applying soda to the conjunctival sac, they become moist and end up with tear fluid, then soften and observe to the ocular surface. This dosage form ensures prolonged effect since the release of the active ingredient(s)from soda is in pulsation and unrestrained style. Examples of drugs employed in soda involve sulphapyridine, neomycin, tetracaine, kanamycin, atropine and pilocarpine. (13,19,20)

**3.3.4. Mini disc/eye therapy system (opts):**

This is (opts) identical to contact lenses with a diameter of 4 to 5 mm. The candidate drugs used in opts are Sul isoxazole and gentamicin sulphate. Ots can be hydrophilic or hydrophobic, allowing for extended-release period of poorly water-soluble and water-soluble active ingredients. Ots has a contoured, convex, concave appearance on the side in contact with the surface of the eye. (19,21)

**3.3.5. Artificial tear insert:**

Artificial tear supplement developed from hydroxypropyl cellulose. It is commercially available under the name laciest. It is used to treat dry eye syndrome. It is a long, stick-shaped pill that contains no preservatives. After inserting the artificial tear pad into the conjunctival sac, the insert will absorb water from the conjunctiva and cornea, forming a hydrophilic layer that stabilizes the tear film and moistens the cornea. (8)

**3.3.6. Collagen shield:**

Collagen shield has been studied in animal and human models and can be used as a carrier for anti-inflammatory drugs for example dexamethasone, antibiotics such as gentamicin or antiviral drugs. The use of collagen shields resulted in higher drug concentrations in the cornea and aqueous humour compared with contact lenses and eye drops. (13,21)

**3.3.7. New eye drops delivery system “nods”:**

Compared with traditional eye drops, nods ensure delivery of the required dose of drug to the eyeball and improves its bioavailability even several times as in the case of pilocarpine combination, in which its bioavailability is increased eightfold. In addition, nods do not contain preservatives and can be sterilized by gamma rays. This ophthalmic drug delivery system has been patented by smith and nephew pharmaceuticals ltd. It consists of a cardboard handle and a polyvinyl alcohol flag (containing the drug) attached to the holder by a dissolving film. A film containing the drug separates from the paper handle at the point of introduction of the drug into the conjunctival sac, which then dissolves in the tear fluid and thereby releases the drug from the film. (22.23)

**3.3.8. Minitablets:**

The candidate drugs which were formulated as minitablets ophthalmic delivery system involved gentamicin, acyclovir, piroxicam, timolol and ciprofloxacin. (23,24) There numerous advantages of minitablets dosage form involving. Resistance to defence mechanisms by tearing or outflow through nasolacrimal duct, easier for introducing to conjunctival sac, longer contact time with the cornea due to the presence of mucoadhesive polymer, and the gradual release of the drug from the preparation at the application site caused by swelling the outer carrier layers. (23,25) Minitablets are biodegradable, solid drug forms, that, later application to conjunctival sac, transit into gels, which extends the time period of contact between active ingredient and the eyeball surface, which in turn increases the active ingredient's bioavailability. (26)

**4.Methods of ophthalmic drug dosage forms:**

**4.1. Conventional ophthalmic dosage forms:**

Solutions are extensively used dosage form for topical transport of therapeutics to the eye. Factors to be taken into consideration in formulating ophthalmic answers are solubility, ocular toxicity, pika, impact of Ph, tonicity, buffer capacity, viscosity, compatibility with different elements withinside the system, preservatives to be used, consolation while instilled into the eye, and the convenience of manufacturing. (3)

**4.2. Viscosity enhancers:**

Polymers are characteristically familiarised to ophthalmic drug answers which will increase the viscosity on the basis and correspond to a slower removal from the preocular area, which cause stepped forward precorneal house time and consequently a larger trans corneal penetration of the drug into the anterior chamber. Natural polymers including ha, vee gum, alginate, xanthan gum, gelatine, acacia and tragacanth can also be used as viscosity improvers. However, they have the disadvantage of harbouring microorganisms and fungi. (3)

**4.3. Permeation enhancers:**

By increasing the permeability of the corneal epithelial membrane, transport done the cornea can be maximized. Cornea, in order to improve the bioavailability of ophthalmic drugs, one of the techniques used is to temporarily increase the permeability properties of the cornea with appropriate materials called penetration enhancers or enhancers. Absorb similar eye infections and poisoning, these are some of the risks. On-line transport from the cornea to the receptor is a rate-limiting step, and permeation enhancers increase corneal absorption by changing the integrity of the corneal epithelium. (3)

**4.4. Pre-medication:**

The principle of pre-medication is to beautify the cornea. Permeability due to changes in the hydrophilic (or lipophilic) nature of the drug. In the cornea or after penetration into the cornea, the prodrug is converted chemically or enzymatically to form the active compound. Therefore, a suitable prodrug must not only have high lipophilicity and high partition coefficient but also must have high enzyme sensitivity. The antiviral drug ganciclovir and acyclovir are the correct prodrugs. (3)

**4.5. Chemical approaches to improve ocular bioavailability:**

The goal of advanced ocular drug delivery is no longer simply to progress ocular drug absorption but also to reduce systemic absorption. Systemic drug absorption is not only ineffective absorption but also leads to drug-related systemic side effects. The maximum vital techniques in chemical procedures for ocular transport are designing pills that go over sequential metabolic conversion and eventually attain the target (retro metabolic design), and designing ocular drug which can be inactive at sites aside from the eye (prodrugs) chemical change of a recognised inactive metabolic or analogy to mending the healing interest that transforms lower back into the inactive metabolite in a predictable one- step biotransformation (Sb). (3)

**5. Examinations of ophthalmic drug forms properties:**

**5.1. In vitro examinations:**

**5.1.1. Sterility examination:**

The basic requirement for drug forms applied on the eyeball is their sterility. Examination of sterility involves inoculation in aseptic conditions of the sample examined on two microbiological media: Thioglycolate medium (fluid sodium decapacitate or sodium thioglycolate), which is used for growth of aerobic and anaerobic bacteria, and medium with hydrolysate of casein and soy (soya-bean casein digest media) used for growth of aerobic bacteria and fungi. A thioglycolate medium with an applied sample is incubated at the temperature of 30–35c, whereas a medium with hydrolysate of casein and soy with an applied sample is incubated at the temperature of 20–25c for the time not shorter than 14 days. Two systems are distinguished for inoculation of examined material: Direct inoculation and a method involving use of membrane filters. (28,29,30) The direct inoculation method, as described in pharmacopoeia, involves transferring the appropriate amount of examined preparation to the medium. If the product has antibacterial properties, this effect of the substance must be neutralized beforehand testing. Before introduction into the medium, the ointment must be diluted with an appropriate sterile solvent containing the selected surfactant. During incubation, the medium containing the sample essential be observed for a specified period of time. (28,30) Indirect methods (membrane filtration methods) are used when the nature of the product allows. For water and oil solutions, cellulose nitrate filters with a pore size of no more than 0.45 𝜇m are used. For certain products, for example antibiotics, specially adapted filters are used. In the case of testing a product with an antibacterial effect, the membrane obligation be washed with the selected sterile solvent at least 3 times, not exceeding 5 filter wash cycles per 100 ml of solvent. The entire membrane is transferred to the appropriate medium or aseptically cut into two identical parts, which are then transferred to two different media. In the case of a water-soluble solid, the substance must be dissolved in a suitable solvent and the subsequent procedure must be the same as for an aqueous solution. The indirect method can also be used for ointments. Fat-based ointments may be diluted with isopropyl myristate if necessary, at a temperature not exceeding 40∘C. In special cases, the high temperature limit may be 44∘C. The product is then filtered as quickly as possible. (28,29)

**5.1.2. Determination of Ph:**

The Ph of topical solutions, drops, suspensions and gels are usually determined by potentiometric methods. In this method, the Ph value is determined by measuring the potential difference between electrode placed in the solution under test and a reference solution of known Ph or between the measuring electrode (glass) and reference electrode (calomel or silver chloride), both of which are placed in the composition being tested. (28, 31,32)

**5.1.3. Clarity test:**

Clarity test comprises include visual evaluation of the formula under appropriate lighting on a white and black background. It is taken in liquid form, except for suspensions. This review applies to topical eye drops and gels before and after gelation. (29,30) Additional method to test clarity is to measure transmittance with a is spectrophotometer. This method can be used in research on active substance-filled contact lenses. The lens was hydrated in physiological serum and placed on the surface of a quartz basin. Transmission was then measured at wavelengths from 200 to 1000 nm. (34)

**5.1.4. Check particle size and morphology:**

The cornea is the most anterior part of the eye, in front of the iris and pupil. It is the densest tissue in the body and most corneal nerves are sensory nerves. Originating from the ophthalmic branch of the trigeminal nerve. Five layers can be distinguished in the human cornea: epithelium, bowman's membrane, lamina propria, Descemet membrane, and filtering endothelium with a pore diameter of 1 𝜇m. This inspection allows them to calculate the number of particles ≥ 10 𝜇m in size in the products tested. Testing starts from low magnification, for example ×10 or ×50, where particles larger than 25 micrometres can be found. (35)

**5.1.5. Stability assessment:**

The purpose of stability assessment is to provide information about changes in the quality of the active ingredient or drug over time due to the influence of environmental factors, i.e., temperature, humidity and light. Of the substance/product tested, as well as setting the date for further testing of the drug substance or the expiration date of the medicinal product and recommended storage conditions. (43) Universal stability requirements for ophthalmic products, such as drops and ointments, are similar to those for other pharmaceutical products. They are harmonized through the ich (international conference on harmonization) process in the United States, Europe and Japan, recognizing the contributions of the European organization EMEA (European medicines evaluation agency) and the special pharmaceutical committee (camp), its twp. (quality working group), and the us fad (food and drug administration) as well as the Japanese ministry of health. (44)

**5.2. Other tests performed for some dosage forms:**

**5.2.1. In situ gel test:**

Test for gel forming ability. This test is performed to evaluate the ability of the formulation to form gel on the ocular surface. A sample of examined formulation is familiarized to a vial containing a solution whose components simulate a tear fluid and visual technique is employed to assess the sol-gel phase transition. (1)

**5.2.2. Examinations for inserts:**

Swelling index. Hydrophilic polymers of different structures exhibition different swelling degree, depending on relative resistance of matrix network structure to water particles' movement. Polymer chains exhibiting low ability to form hydrogen bonds may not be able to form strong network structure, resistant to fast water penetration. Therefore, this parameter is extremely important for predicting drug release and bio adhesive matrix potential. The swelling test is performed to measure the overall hydrophilicity and hydration of the polymer. (42)

**5.3. In vivo testing:**

**5.3.1. Eye irritation test (Draize eye test):**

There are many adjustments to the eye irritation/toxicity test (Draize eye test Draize) is made for dosage forms, i.e. Solutions, emulsions, ointments, solids, e.g. Inserts, etc. Testing is typically performed on rabbits, whose anatomy and physiology of the visual organs are well described in the literature. After familiarizing the medicinal form into the eyeball, the eyelids usually close for a few seconds, although this is not required. Sometimes a sterile solution is also used to wash the ocular surface. Evaluation of the condition of the eyeball before and after application of the formulation is performed by observing the eyeball under appropriate lighting, often using a magnifying glass or slit lamp to guarantee a more accurate assessment. Evaluation usually takes place 1 h, 24 h, 48 h and 72 h after intraocular administration of the formulation and, if necessary, also after 7 or 21 days. The test time, as well as its scheme, is individually adapted to the formulation being analysed. Ocular changes were evaluated using a scoring system in which each change in the eyelid, conjunctiva, cornea, and iris regions was noted. Although numerous scoring systems have been proposed in the literature, the modified methods of Frieden Wald and Draize are still widely used. (42,33,30,46,)

**5.3.2. Corneal permeation studies:**

For corneal permeation studies, as in the Draize eye test, healthy albino rabbits are selected in allowed numbers obtain reliable results. The amount of active ingredient in the aqueous humour after introduction of the formulation into the conjunctival sac was marked at defined time breaks. Using a syringe fitted with a needle, after an intramuscular or intravenous injection of an aesthetic that may comprise, depending on the application, ketamine hydrochloride, xylazine hydrochloride or sodium pentobarbital, an aqueous solution of the mood sample is taken at a rate of approximately 150 to 200 µl and store at negative temperature. Temperature, for example −20 °c, before plc analysis. (45)

**5.3.4. Evaluation of in vivo release of the insert:**

To evaluate in vivo release, the formulas that yielded the desired results in the in vitro release assessment was selected. Inserts were placed into the conjunctival sacs of healthy rabbits selected for study. At specified intervals, the inserts were prudently removed and examined to determine the amount of drug remaining using appropriate analytical techniques. (47)

**6. Advantages:**

1) Their aids encompass convenient management and acknowledge reliability.

2) Eye emulsions offer the advantage of effectively carrying hydrophilic medications, while

Oil-in-water (O/W) emulsions are less likely to cause irritation to the eye.

3) Inserts, on the other hand, provide advantage such as prolonged duration of action sustained drug release, consistent dosage, and minimized adverse effects. (48)

4) The ocular route has quicker drug absorption and less systemic and visual side effects.

1. By avoiding the pulsed doses of conventional systems, it offers accuracy and uniformity in dose rate.
2. It offers better covering of delivery systems. (49)

**7. Disadvantage:**

1) The major disadvantage of the ocular route of drug administration is that the rapid and extensive exclusion of traditional eye drops which can cause widespread loss of drug resulting in poor retention of the drug at the site of action.

2) The rapid elimination of the medication through tear flow and eye blink results in a short period of therapeutic effect, which can lead to frequent dosing.

3) Afterward application of the ointment, drops, and other medication may be a temporary blurring of vision.

4) Limited medications are suitable to formulate for the ocular route.

5) It has limited permeability to the cornea resulting in reduced absorption of ophthalmic drugs. (49)

**8.** **Case Study of Ophthalmic Drug Dosage Forms:**

**8.1. Case Study 1: Acute R Eye Pain:**

**Diagnosis:**

Suspected acute angle closure glaucoma R eye.

Narrow angle L eye.

**Differential Diagnosis:**

The affected person described is imparting with acute angle closure glaucoma because of shallow anterior chamber angles. Other causes of boom intraocular pressure consist of open angle glaucoma or different pathology of the trabecular meshwork (pigmentary dispersion, pseudo exfoliation, trauma, neovascularization, etc). That obstructs aqueous outflow. Ahead displacement of intraocular structures (posterior tumour, choroidal swelling, and so forth). Also, can block the outflow of aqueous and multiplied the intraocular stress.

**Definition:**

Acute attitude closure glaucoma happens when there's a particularly sudden blockage of the trabecular meshwork causing elevation of the intraocular strain.

**Examination:**

Acute perspective closure normally offers with intense ocular pain, headache, blurred imaginative and prescient, halos round lights, nausea, and vomiting. Some of the obvious non-ocular manifestations (nausea/vomiting) will be deceptive to the green doctor. However, the activate popularity and next treatment of an acute attitude closure disaster is paramount within the protection of the patient imaginative and prescient shared eye examination findings as in this affected person, consist of moderate conjunctival injection, hazy cornea, mid dilated pupil, shallow attitude and faster intraocular pressure. Angle closure high quality determined the use of a gonioscopy contact lens that permits the viewer to see into the perspective of the attention even supposing acute episode is recognized and treated speedy and correctly, there can still be optic nerve damage and resultant visual loss every other viable alternate of iris ischemia which could cause sloughing of iris pigment. Pigments may be cited inside the anterior chamber and on the corneal endothelium. Iris damage may additionally motive the pupil to remain in a dilated function. The intraocular may moreover upward push sufficient to cause retinal vascular occlusion and retinal ischemia. Anterior subcapsular lens opacities additionally arise due to ischemia.

**Treatment:**

Treatment of acute attitude closure glaucoma is either laser or surgical peripheral iridectomy (putting a hole in the peripheral iris). This procedure restores aqueous flow from the posterior to anterior chamber through developing an additional starting within the iris, relieving the pathologic strain gradient. This in the end lets in the iris to regress and shrink back from the trabecular meshwork and then regular aqueous humour drainage is restored. This system is frequently curative of the affected eye. A prophylactic peripheral iridectomy of the non-affected eye is important to save you an episode from happening within the fellow eye. Individuals with one episode of acute perspective closure glaucoma have an excessive probability of an attack inside the fallow eye over next 5-10 years. Even when the intraocular strain has decreased subsequent follow up is essential to be sure that the perspective remains open. Iop might also lower soon after the assault because of ciliary frame ischemia and decreased aqueous humour production and no longer because the attitude has reopened. (50)

**8.2. Case Study 3: Eye irritation and dryness:**

**Diagnosis:**

Graves ophthalmopathy**.**

**Differential Diagnosis:**

This patient with viable Graves ophthalmopathy, additionally know as thyroid ophthalmopathy. Different illnesses inside the differential diagnosis consist of conditions that reason orbital congestion (orbital tumours, orbital infections like orbital cellulitis), other causes of orbital inflammation.

**Definition:**

Grave's ophthalmopathy takes place secondary to an autoimmune system which leads to modifications in orbital content (especially extraocular muscle mass and orbital fats).

**Examination:**

Signs and symptoms may additionally consist of upper and decrease eyelid retraction, dry eyes, double imaginative and prescient, limit of extraocular actions, excessive tearing, and eye inflammation. Examination findings may additionally show exophthalmos or proptosis (ahead motion of the globe), lagophthalmos (inability to close eyes), strabismus (misalignment of eyes), swelling of the eyelids, corneal dryness chemosis of the conjugative accelerated intraocular stress, and in severe instances, congestion of the optic nerve via the swollen orbital systems and vision loss.

**Treatment:**

Treatment of Graves ophthalmopathy unbiased of systemic illness. Remedy relies upon on signs and symptoms and severity of sickness. Artificial tears may be used for corneal publicity. Eyelid surgical treatment may be considered for excessive lid retraction. High dose glucocorticoids are used for intense orbital congestion and optic neuropathy. Steroid-sparring sellers and extra immunomodulators also are used (cyclosporine, azathioprine). Now and optic, surgical decompression of the orbit is needed to save you extreme exophthalmos and optic nerve compression. If patients expand diplopia secondary to muscle growth and fibrosis, prisms and then strabismus surgery are presented after the inflammatory response is controlled. Eyelid surgical treatment is differed in sufferers which have extreme publicity due to a fibrotic elevator muscle. Most instances of Graves Ophthalmopathy stabilize inside 8-36 months. (51)

**9. Conclusions:**

Despite many achievements in the discipline of ophthalmic dosage paperwork, nevertheless substantial common of active materials for use in ocular problems are inside the fore of eye drops. In connection with the improvement of latest ophthalmic dosage paperwork, hassle regarding the evaluation in their physiochemical houses an in vitro-in vivo correlation appears. In the treatment of eye disease, the ocular inserts represent a widespread advancement. This device of ousters presents many benefit’s includes with; enhance affected person compliance through manner of method of decreasing the frequency of dosing offer sustained and controlled drug delivery and decrease the dose and there by lessen the adverse effects of the drug. This paper is a evaluate of the obtainable literature which allows planning research to be conducted on standard and contemporary ophthalmic drug forms.

**10. Reference:**

1. Przemysbaw Baranowski, Bohemia karyologic, et al. Ophthalmic drug dosage forms: characterisation and research methods. Hinda Wi publishing corporation e scientific world journal volume 2014, article in 861904, 14 pages <http://dx.doi.org/10.1155/2014/861904>.

2. Duaa j. Al-tamimi1, Afaq m. Ammo, et al. Review article ophthalmic dosage forms Kerbala journal of pharmaceutical science no (18) received (april-2020), accepted (april-2020) drjaafarjaber@yahoo.com.

3. Priti bokil1,Dr. Gajanan sanap2, et al. Published by international journal of advanced research in science, communication and technology Doi: 10.48175/568 page no 324 to 326.

4. Gan l, wang j, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug discovery. pmid:23092895 Doi: [10.1016/j.drudis.2012.10.005](https://doi.org/10.1016/j.drudis.2012.10.005) today 2013; 18, page no 290-297.

5. Le Bourdais c, Scar l, et al. Ophthalmic drug delivery systems—recent advances pmid:9537794 Doi: [10.1016/s1350-9462(97)00002-5](https://doi.org/10.1016/s1350-9462%2897%2900002-5). Prog. Retin. Eye res. 1998; 17, page no 33–58.

6. P. Pahuja, s. Arora, et al. “Ocular drug delivery system: a reference to natural polymers,” expert opinion on drug delivery January 2022. Doi:[10.1016/b978-0-323-85873-1.00005-8](http://dx.doi.org/10.1016/B978-0-323-85873-1.00005-8) , vol. 9, no. 7, page no 837–861, 2012.

7. R. Gaudian, j. Jwala, et al. “Recent perspectives in ocular drug delivery,” pharmaceutical research, <http://dx.doi.org/10.1155/2014/861904> vol. 26, no. 5, page no 1197–1216, 2009.

8. P. Tangri and s. Khurana, et al. “Basics of ocular drug delivery systems,” international journal research in pharmaceutical and biomedical sciences,[www.ijrpbsonline.com](http://www.ijrpbsonline.com) vol. 2, no. 4, page no 1541–1552.

9. “The international pharmacopoeia,” 4th edition, 2013, <http://apps.who.int/phint/en/p/about/>.

10. Jitendra, p. K. Sharma, et al. “A new trend: ocular drug delivery system,” an international journal of pharmaceutical sciences, vol. 2, no. 3, page no 1–25, 2011.

11. M. Yamaguchi, S.-I Yasuda, et al. “formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluorinated,” international journal of pharmaceutics, <https://doi.org/10.1016/j.ijpharm.2005.05.036> vol. 301, no. 1-2, page no 121–128, 2005.

12. Jurvanen t, Jurvanen k, et al. Prodrugs for improved ocular drug delivery. Advanced drug delivery reviews. [Https://doi.org/10.1016/0169-409x(95)00107](https://doi.org/10.1016/0169-409X%2895%2900107) . 1996;19(2) page no 203–224.

13. Rajasekaran a, Kumaran sag, et al. A comparative review on conventional and advanced ocular drug delivery formulations. International journal of Partech research. 2010;2(1): page no 668–674.

14. K. S. Rathore and r. K. Nama, et al. “an insight into ophthalmic drug delivery system,” international journal of pharmaceutical sciences and drug research, [https://doi.org/10.25004/ijpsdr.2009.010101](https://doi.org/10.25004/IJPSDR.2009.010101) vol. 1, no. 1, page no 1–5, 2009.

15. Richard su¨verkru¨pa, \* Sabine grunt Hala, et al. Michael distalmost the ophthalmic lyophilizate carrier system (olms) European journal of pharmaceutics and biopharmaceutics 57 (2004) page no 269–277 [www.elsevier.com/locate/ejpb](http://www.elsevier.com/locate/ejpb)

16. Christle le Boulais I, Liliane acer 1, et al. Ophthalmic drug delivery systems recent advances progress in retinal and eye research pmid:9537794 Doi: [10.1016/s1350-9462(97)00002-5](https://doi.org/10.1016/s1350-9462%2897%2900002-5) vol. 17, no. 1, page no 33-58, 1998

17. M. H. Abraham, A. A. Mahmoud, et al. “Biodegradable ocular inserts for sustained delivery of brimonidine tartrate: preparation and in vitro/in vivo evaluation,” asps pharm SciTech, pmid:21979886 Doi: [10.1208/s12249-011-9701-3](https://doi.org/10.1208/s12249-011-9701-3) vol.12, no. 4, page no 1335–1347, 2011.

18. G. Venkata Ratnam, S. Madhavi, et al. “Ocular drug delivery: an update review,” international journal of pharmacy and biological sciences, vol. 1, no. 4, page no 437–446,2011  venkatgogusetti@gmail.com

19. Shiv hare r, Pathak a, et al. An update review on novel advanced ocular drug delivery system. World journal of pharmacy and pharmaceutical sciences. 2012; vol.1, no.2, page no 545–568.www.wjpps.com

20. Marchuk yf. Ophthalmic drug inserts. Investigative ophthalmology. 1975; vol.14, no.2, page no 87–90. pmid:1112643

21. Karthikeyan d, Bhowmik m, et al. The concept of ocular inserts as drug delivery systems: an overview. Asian journal of pharmaceutics. 2008; vol.2, no. 4, page no 192–200. [Https://doi.org/10.22377/ajp.v2i4.204](https://doi.org/10.22377/ajp.v2i4.204).

22. Lloyd r. Applicants for pharmaceutically active agents, their preparation and use. U.k. intellectual property office, lb, 2097680 a, 19821110, 1982.

23. Diestel horst m, Krieg stein gk.et al. The ocular tolerability of a new ophthalmic drug delivery system (nods). International ophthalmology. 1994; vol.18, no.1, page no 1–4.[https://doi.org/10.1007/bf00919405](https://doi.org/10.1007/BF00919405) .

24. Moosa rm, Chanara ye, et al. A review of topically administered mini-tablets for drug delivery to the anterior segment of the eye. Journal of pharmacy and pharmacology. 2013; 66(4): Doi: [10.1111/jphp.12131](https://doi.org/10.1111/jphp.12131). Pmid:24635554. page no 490-506

25. Mortazavi sa, Jaffar Azar z, et al. Formulation and in-vitro evaluation of ocular ciprofloxacin-containing minitablets prepared with different combinations of Carbopol 974p and various cellulose derivatives. Iranian journal of pharmaceutical research. 2010; vol.9, no.2, pmcid:[pmc3862056](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc3862056/). pmid:24363715. Page no 107–114.

26 Abd El Gawad h, Solimano, et al. Formulation and evaluation of gel forming ocular minitablets containing piroxicam. British journal of pharmaceutical research. 2012; vol.2, no. 3. Doi:[10.9734/bjpr/2012/1653](http://dx.doi.org/10.9734/BJPR/2012/1653). Page no141–167

27. W. Weyenberg, a. Vermeire, et al, “Effects of roller compaction settings on the preparation of bio adhesive granules and ocular minitablets, “European journal of pharmaceutics and biopharmaceutics, vol.59, no. 3. Doi: [10.1016/j.ejpb.2004.09.012](https://doi.org/10.1016/j.ejpb.2004.09.012) page no 527–536,

28. t. Loftsson, e. Stefansson, et al. “Cyclodextrins in eye drop ´formulations: enhanced topical delivery of corticosteroids to the eye,” acta ophthalmological Scandinavica, vol. 80, no. 2. [Https://doi.org/10.1034/j.1600-0420.2002.800205.x](https://doi.org/10.1034/j.1600-0420.2002.800205.x) page no 144–150, 2002.

29. “The international pharmacopoeia,” 4th edition, 2013,[http://apps.who.int/pint/in/p/about/](http://apps.who.int/phint/en/p/about/).

30. B. K. Nonjaded, B. Soneji, et al. “preparation and evaluation of eye-drops for the treatment of bacterial conjunct Tavitas,” journal of pharmaceutics and cosmetology, vol. 1, no. 2, page no 43–49, 2011.

31. S. Nagarro, A. Phatak, et al. “for emulation and evaluation of ophthalmic delivery of fluconazole from ion activated in situ gelling system,” der Pharmacia letter, vol. 4, no. 4, page no 1228–1235, 2012.

32. l. Budai, m. Hajdu, m. Budai et al., “gels and liposomes ´in optimized ocular drug delivery: studies on ciprofloxacin formulations,” international journal of pharmaceutics, vol. 343, no. 1-2, Doi: [10.1016/j.ijpharm.2007.04.013](https://doi.org/10.1016/j.ijpharm.2007.04.013). page no 34–40, 2007

33. T. F. Vandamme and l. Brock, et al. “poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide,” journal of controlled release, vol. 102, no. 1, .<https://doi.org/10.1016/j.jconrel.2004.09.015> page no 23–38, 2005

34. H. J. Jung, m. Abou-jade, et al. “glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses,” journal of controlled release, vol. 165, no. 1, page no 82–89, 2013.

35. T. K. Das, et al. “Protein particulate detection issues in biotherapeutics development-current status,” aps pharm SciTech, vol. 13, no. 2, Doi: [10.1208/s12249-012-97934](https://doi.org/10.1208/s12249-012-9793-4) page no 732–746, 2012

36. Marion doubled 1,2, Sandrine bourgeois 1,3, et al. Véronique Andreu ophthalmic drug delivery systems for ant biotherapy doi:10.3390/pharmaceutics10010010 [www.mdpi.com](http://www.mdpi.com).

37. Achouri d, Alnmouth k, et al. Recent advances in ocular drug delivery. Drug dev in pharm. 2013 nov;39(11):1599-617. Doi:10.3109/03639045.2012.736515. Epub2012 Nov. 16. Pmid:23153114.

38. Djamila achouri1,2,4, Kamel alhanout3,4,5, et al. Véronique Andreu drug development and industrial pharmacy, 2012; early online: 1–19 © 2012 Informa healthcare USA, inc. Doi: 10.3109/03639045.2012.736515.

39. Colin e Willoughby md, PhD, et al. free access anatomy and physiology of the human eye: effects of mucopolysaccharidoses disease on structure and function. Clinical & experimental ophthalmology volume 38, issue s1 <https://doi.org/10.1111/j.1442-9071.2010.02363>.

40. Mica vs.et al. The eye and visual nervous system: anatomy, physiology and toxicology. Environmental health perspectives, Doi: 10.1289/ehp.82441 1982; 44: page no1-8

41. 1tahura.s. Sayed, 2dr. Effat Rizwan, et al. A review on quality analysis and evaluation of ophthalmic products 2021 jitter September 2021, volume 8, issue 9 [www.jetir.org](http://www.jetir.org) .

42. M. H. Abraham, a. A. Mahmoud, et al. “Biodegradable ocular inserts for sustained delivery of brimonidine tartrate: preparation and in vitro/in vivo evaluation,” asap pharm SciTech, vol.12, no. 4, Doi: [10.1208/s12249-011-9701-3](https://doi.org/10.1208/s12249-011-9701-3) page no 1335–1347, 2011

43. International conference on harmonization, “stability testing of new drug substances and products q1a (r2),” federal register, vol. 68, no. 225, page no 65717–65718, 2003.

44. B. R. Matthews and g. M. Wall, et al. “Stability storage and testing of ophthalmic products for global registration,” drug development and industrial pharmacy, vol. 26, no. 12, page no 122712

45. Noomwong p, Ratana Sak w, et al. Development of acyclovir-loaded bovine serum albumin nanoparticles for ocular drug delivery. International journal of drug delivery. 2011;3(4): page no 669–675.

46. Prajapati pa, Patel mm, et al. Formulation and in vitro evaluation of atropine sulphate viscous ocular solutions for the mydriatic and cycloplegic effect. International journal of pharmaceutical and applied sciences. 2010;1(2): page no 70–78.

47. Mundia as, Shrikhande bk, et al. Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride. Drug development and industrial pharmacy. 2006;32(4): pmid:16638682 Doi: [10.1080/03639040500534101](https://doi.org/10.1080/03639040500534101) pmid:16638682: page no 443–448

48. Sadek Ahmed, Maha M. Amin, et al., Ocular Drug Delivery: a Comprehensive Review, / Published by- AAPS Pharm SciTech (2023), <https://doi.org/10.1208/s12249-023-02516-9>, Page no. 1-29

49. [Chromeno: Advantages and disadvantages of ocular route of drug administration](https://chrominfo.blogspot.com/2021/02/Advantages-and-disadvantages-of-ocular-route-of-drug-administration.html)

50. Dale E, Fajardo, et al. American academy of ophthalmology 2009. [Ophthalmic Case Study 1 | Ophthalmology and Visual Sciences | Medical College of Wisconsin (mcw.edu)](https://www.mcw.edu/departments/ophthalmology-eye-institute/education/ophthalmic-case-studies/ophthalmic-case-study-1)

51. Rajat Maheshwari, Ezekiel Weis, et al. Thyroid associated orbitopathy. Indian ophthalmic 2022 Mar-Apr 60(2) page no: 87-93. Doi: [10.4103/0301-4738.94048](https://doi.org/10.4103/0301-4738.94048).